Regulus Therapeutics Inc. Daily Stock Analysis

Daily Stock Analysis, RGLS, Regulus Therapeutics Inc, priceseries

Regulus Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
0.30
Close
0.29
High
0.33
Low
0.29
Previous Close
0.29
Daily Price Gain
0.00
YTD High
0.34
YTD High Date
Jan 5, 2022
YTD Low
0.19
YTD Low Date
Jan 25, 2022
YTD Price Change
-0.04
YTD Gain
-11.52%
52 Week High
2.32
52 Week High Date
Mar 12, 2021
52 Week Low
0.19
52 Week Low Date
Jan 25, 2022
52 Week Price Change
-0.99
52 Week Gain
-77.19%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 6. 2017
13.50
Mar 16. 2017
14.32
8 Trading Days
6.06%
Link
LONG
Mar 24. 2017
16.80
Apr 3. 2017
18.08
6 Trading Days
7.61%
Link
LONG
Jul 21. 2017
11.76
Jul 28. 2017
12.39
5 Trading Days
5.36%
Link
LONG
Sep 6. 2017
12.24
Sep 28. 2017
15.75
16 Trading Days
28.65%
Link
LONG
Dec 29. 2017
12.48
Jan 9. 2018
13.50
6 Trading Days
8.21%
Link
LONG
Aug 14. 2018
3.16
Aug 15. 2018
3.32
1 Trading Days
5.10%
Link
LONG
Sep 26. 2018
2.46
Sep 28. 2018
2.61
2 Trading Days
6.07%
Link
LONG
Oct 3. 2018
2.52
Oct 4. 2018
2.79
1 Trading Days
10.52%
Link
LONG
Feb 22. 2019
1.06
Mar 4. 2019
1.16
6 Trading Days
9.79%
Link
LONG
May 6. 2019
1.26
May 7. 2019
1.33
1 Trading Days
5.56%
Link
LONG
Dec 26. 2019
0.68
Jan 23. 2020
1.18
18 Trading Days
74.87%
Link
LONG
Nov 25. 2020
0.61
Dec 29. 2020
1.27
22 Trading Days
108.15%
Link
LONG
Jan 21. 2021
1.23
Feb 22. 2021
1.73
21 Trading Days
40.74%
Link
Company Information
Stock Symbol
RGLS
Exchange
NasdaqGM
Company URL
http://www.regulusrx.com
Company Phone
858-202-6300
CEO
Paul C. Grint
Headquarters
California
Business Address
10614 SCIENCE CENTER DRIVE, SAN DIEGO, CA 92121
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001505512
About

Regulus Therapeutics, Inc. engages in the discovery and development of drugs targeting microRNAs. It is developing RG-101, which targets miR-122, a host factor for the hepatitis C virus infection. The company was founded in September 2007 and is headquartered in San Diego, CA.

Description

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. The company uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides. Its clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 for the treatment of non-alcoholic fatty liver disease; RGLS5040, an anti-miR targeting microRNA-27 for the treatment of cholestatic disease; and RGLS4326, an anti-miR targeting microRNA-17 for the treatment of autosomal dominant polycystic kidney disease. The company has strategic alliance with AstraZeneca AB and Sanofi to discover, develop, and commercialize microRNA therapeutics; and Biogen Inc. on microRNA biomarkers for multiple sclerosis, as well as a clinical trial collaboration agreement with GSK LLC. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading